%0 Journal Article
%T Rivaroxaban e malattia renale cronica: evidenze dal presente e prospettive future
%A Antonio Bellasi
%A Antonio De Pascalis
%A Claudio Ronco
%A Fulvio Floccari
%A Luca Di Lullo
%A Rodolfo Rivera
%A Vincenzo Barbera
%J Giornale di Tecniche Nefrologiche e Dialitiche
%@ 1724-5974
%D 2019
%R 10.1177/0394936219836652
%X Rivaroxaban and Chronic Kidney Disease: evidence from the present and future prospects Cardiovascular diseases represent the main cause of comorbidly in chronic kidney disease (CKD) patients, with a 7% incidence in atrial fibrillation (AF) in end-stage renal disease (ESRD) patients. Until recently, prophylactic treatment of atrial fibrillation complications (such as thromboembolism) was mainly based on vitamin K antagonists (VKA) or heparin. In the last years, direct oral anticoagulants (DOACs) have been made available; however, their renal clearance limits their use on patients with severe renal impairment (eGFR <15 mL/min). Among DOACs, Rivaroxaban, a factor X-activated (Xa) inhibitor, shows good renal profile and it can be used in CKD patients up to stage 4 as well as in ESRD patients (at the moment only in North America and Canada)
%K Atrial fibrillation
%K Chronic kidney disease
%K Warfarin
%K Direct oral anticoagulants
%K Rivaroxaban
%U https://journals.sagepub.com/doi/full/10.1177/0394936219836652